Analysts See $0.54 EPS for Innoviva, Inc. (INVA)

April 25, 2018 - By Richard Conner

Analysts expect Innoviva, Inc. (NASDAQ:INVA) to report $0.54 EPS on April, 26.They anticipate $0.39 EPS change or 260.00 % from last quarter’s $0.15 EPS. INVA’s profit would be $54.63 million giving it 6.71 P/E if the $0.54 EPS is correct. After having $0.50 EPS previously, Innoviva, Inc.’s analysts see 8.00 % EPS growth. The stock decreased 8.17% or $1.29 during the last trading session, reaching $14.5. About 1.03 million shares traded. Innoviva, Inc. (NASDAQ:INVA) has risen 27.80% since April 25, 2017 and is uptrending. It has outperformed by 16.25% the S&P500.

Innoviva, Inc. engages in the development and commercialization of bio-pharmaceuticals. The company has market cap of $1.47 billion. The Company’s portfolio of respiratory products include RELVAR/BREO ELLIPTA, and ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI). It has a 12.44 P/E ratio. The company, under its the Long-Acting Beta2 Agonist (LABA) collaboration agreement and the strategic alliance agreement with Glaxo Group Limited (GSK), is entitled to receive royalties on the sales of RELVAR/BREO ELLIPTA; and a 15% of any future payments made by GSK under its agreements relating to the combination FF/UMEC/VI and the Bifunctional Muscarinic Antagonist-Beta2 Agonist program, as monotherapy and in combination with other therapeutically active components.

Innoviva, Inc. (NASDAQ:INVA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: